We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

136 hedge funds and large institutions have $316M invested in Rigel Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 46 increasing their positions, 37 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

24% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 37

15% more capital invested

Capital invested by funds: $276M → $316M (+$40.3M)

4% more funds holding

Funds holding: 131 → 136 (+5)

0.03% more ownership

Funds ownership: 8.8% → 8.83% (+0.03%)

82% less call options, than puts

Call options by funds: $16K | Put options by funds: $89K

Holders
136
Holders Change
+5
Holders Change %
+3.82%
% of All Funds
2.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
46
Reduced
37
Closed
14
Calls
$16K
Puts
$89K
Net Calls
-$73K
Net Calls Change
-$104K

Top Buyers

1
RSCM
Rock Springs Capital Management
Maryland
+$2.67M
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.23M
3
Morgan Stanley
Morgan Stanley
New York
+$2.11M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.9M
5
Millennium Management
Millennium Management
New York
+$1.81M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$10.7M
2
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
California
-$1.35M
3
Marshall Wace
Marshall Wace
United Kingdom
-$1.33M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.02M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$48.9M -$1.01M -48,880 -2%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$36M -$10.7M -519,086 -24%
BlackRock
3
BlackRock
New York
$31.5M -$283K -13,746 -0.9%
Vanguard Group
4
Vanguard Group
Pennsylvania
$18.9M +$1.03M +49,820 +6%
Millennium Management
5
Millennium Management
New York
$18.2M +$1.81M +87,730 +11%
TA
6
Tamarack Advisers
California
$11.8M +$566K +27,500 +5%
RSCM
7
Rock Springs Capital Management
Maryland
$11.8M +$2.67M +129,790 +31%
Invesco
8
Invesco
Georgia
$10.7M – – –
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$8.19M +$24.1K +1,171 +0.3%
Citadel Advisors
10
Citadel Advisors
Florida
$7.95M -$90.2K -4,383 -1%
State Street
11
State Street
Massachusetts
$7.87M +$560K +27,194 +8%
PAI
12
Palo Alto Investors
California
$7.58M -$92.2K -4,480 -1%
NMC
13
NEA Management Company
Maryland
$6.94M – – –
Goldman Sachs
14
Goldman Sachs
New York
$6.66M +$438K +21,287 +7%
Hudson Bay Capital Management
15
Hudson Bay Capital Management
Connecticut
$6.42M +$515K +25,000 +9%
Renaissance Technologies
16
Renaissance Technologies
New York
$6.37M +$2.23M +108,230 +57%
CS
17
Candriam SCA
Luxembourg
$5.23M -$72.1K -3,500 -1%
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$5.21M -$534K -25,960 -10%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$4.83M -$158K -7,661 -3%
Northern Trust
20
Northern Trust
Illinois
$4.58M +$111K +5,382 +3%
RPAM
21
Rhenman & Partners Asset Management
Sweden
$4.07M -$206K -10,000 -5%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$3.77M +$1.9M +92,137 +110%
Macquarie Group
23
Macquarie Group
Australia
$3.42M – – –
Two Sigma Investments
24
Two Sigma Investments
New York
$2.78M +$289K +14,013 +12%
Morgan Stanley
25
Morgan Stanley
New York
$2.37M +$2.11M +102,385 +1,246%
1
2 3 4 5

RIGL Hedge Fund Activity: Q4 2019 in Review

136 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2019, worth a combined $316M — up 15% from $276M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RIGL positions and 14 closed out — a net gain of 6 holders — while 46 added to existing stakes and 37 trimmed.

The largest buyer was Rock Springs Capital Management, adding an estimated $2.67M. The largest seller was Wellington Management Group, cutting an estimated $10.7M.

  • 136 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2019, up from 131 in Q3 2019.
  • Funds reported $316M of Rigel Pharmaceuticals stock for Q4 2019, up 15% quarter-over-quarter.
  • 20 funds opened new Rigel Pharmaceuticals positions in Q4 2019 and 14 closed out, a net change of +6 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2019 was Rock Springs Capital Management, an estimated $2.67M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2019 was Wellington Management Group, an estimated $10.7M sold.

Based on aggregated 13F filings for Q4 2019.